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The post-genomic era has unveiled the existence of a large repertory of non-coding RNAs and repetitive
elements that play a fundamental role in cellular homeostasis and dysfunction. These may represent
unprecedented opportunities to modify gene expression at the right time in the correct space in vivo,
providing an almost unlimited reservoir of new potential pharmacological agents. Hijacking their mode
of actions, the druggable genome can be extended to regulatory RNAs and DNA elements in a scalable
fashion.
Here, we discuss the state-of-the–art of nucleic acid-based drugs to treat neurodegenerative diseases.
Beneﬁcial effects can be obtained by inhibiting (Yin) and increasing (Yang) gene expression, depending
on the disease and the drug target. Together with the description of the current use of inhibitory RNAs
(small inhibitory RNAs and antisense oligonucleotides) in animal models and clinical trials, we discuss
the molecular basis and applications of new classes of activatory RNAs at transcriptional (RNAa) and
translational (SINEUP) levels.
© 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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In the last years, our understanding of the functional output of
the mammalian genome has enormously increased. This has led to
profound changes in the current view of how a cell works and how
evolution has shaped biological complexity. These discoveries
provide new opportunities for translational research with a
potentially great impact on molecular medicine.
The classic approach to drug discovery has stemmed from the
concept that genomes contain the information to encode for
proteins and these are the building blocks of organisms. Proteome
complexity is the way to structure cells and tissues with different
shapes and functions. Drugs are therefore modiﬁers of protein
activities inhibiting or activating speciﬁc signaling pathways.
Despite a long list of success stories that have positively affected
the well being of patients, this approach has posed tremendous
challenges to drug discovery, resulting in staggering costs, poor
speciﬁcities and difﬁculties in addressing major complex diseases.
Importantly, it has negatively impacted the ability to address rare
diseases that present highly heterogeneous molecular proﬁles in
spite of the small number of patients. Many proteins remain
difﬁcult to be targeted, limiting the repertory of therapeutics.
The sequence of the human genome has conﬁrmed that less
than 5% is involved in encoding proteins, leaving the remaining
sequences, the so-called Junk DNA, with no function and therefore
no role in pharmacology.
A pioneering work previously showed that Junk DNA might
indeed be transcribed unveiling the existence of small RNAs and
the expression of repetitive elements (Klein et al., 1974). However,
the ﬁrst evidence that these unconventional transcripts may have
an important functional role comes from the discovery of RNA
interference in the late 1990s (Fire et al., 1998). Immediately, it was
evident that these RNAs may provide a new class of nucleic acid-
based drugs to inhibit gene expression in vivo. As for the discovery
of recombinant molecular antibodies, the initial excitement and
the consequent large investments crashed against technicalPlease cite this article in press as: S. Gustincich, et al., The Yin and Yang
http://dx.doi.org/10.1016/j.pneurobio.2016.11.001difﬁculties that seemed unsolvable. Two decades later, we are
now witnessing a renaissance of interest in small inhibitory RNAs
due to the reﬁnement of RNA targeting and the optimization of in
vivo delivery. More than 50 RNA molecules and their derivatives
are currently formulated as drugs and being tested in clinical trials
for a number of disorders across different organs. Overcoming
initial failures, we have now entered a second phase of RNA
therapeutics, where we can optimistically expect to witness the
ﬁrst real impact of RNA medicine on patients and society.
Meantime, large genomic projects as those from the ENCODE
(Derrien et al., 2012) and FANTOM Consortia (Forrest et al., 2014)
have increased enormously the description of the molecular
constituents of cells and have contributed to hamper the classical
view of gene expression regulation. In addition to a previously
underestimated number of alternative variants for protein-coding
genes, pervasive transcription of the mammalian genome gives
rise to a large repertory of non-coding transcripts, whose
expression is tightly regulated in space and time. These include
long non-coding RNAs (lncRNAs), small non-coding RNAs and
transcripts derived from Transposable Elements (TEs), such as SINE
(short interspersed nuclear element) and LINE (long interspersed
nuclear element) (Faulkner et al., 2009; Fort et al., 2014; Kapranov
et al., 2010; Katayama et al., 2005). Interestingly, the vast majority
of genomic loci are extensively transcribed from both strands
where two genes are located in opposite orientation, giving rise to
Sense/Antisense pairs (S/AS) (Derrien et al., 2012; Katayama et al.,
2005).
In this context, it is becoming evident that the major
transcriptional output of mammalian cells is represented by
lncRNAs. While functional annotation of the genome has
previously revealed almost 15,000 independent lncRNA genes
(Derrien et al., 2012), the most recent version of LNCpedia database
contains more than 90,000 annotated human lncRNAs (Volders
et al., 2015). By deﬁnition, lncRNAs are transcripts longer than 250
nucleotides, with features similar to those of protein-coding genes
but without a functional open reading frame (ORF). lncRNAs of nucleic acid-based therapy in the brain, Prog. Neurobiol. (2016),
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typically composed by 2–3 exons and may have introns, which are
removed during processing (Derrien et al., 2012). The majority of
lncRNAs are enriched in the nucleus, albeit they can exert their
functions both in nuclear and cytoplasmic compartments. They can
be classiﬁed according to their genomic position relative to nearby
genes. When lncRNAs are distant from other protein-coding or
non-coding genes, they are referred to as long intergenic non-
coding RNAs (or lincRNAs). When they entirely or partially overlap
with other genes, they are deﬁned as genic lncRNAs. In most cases,
the overlap is between a protein-coding gene on one ﬁlament and
an antisense lncRNA on the opposite strand. This genomic
architecture gives rise to natural AS lncRNAs, which are estimated
to cover almost all protein-coding genes, potentially regulating
their expression (Derrien et al., 2012; Katayama et al., 2005).
An increasing number of studies are unveiling lncRNA
functions. As representative examples, in the nucleus lncRNAs
can have enhancer-like activity (Ørom et al., 2010), they may
control the epigenetic status of the chromatin by recruiting
Polycomb Repressor Complex (Rinn et al., 2007) and they can act as
decoy for inhibiting splicing and mRNA maturation (Tripathi et al.,
2010). In the cytoplasm, lncRNAs were described to activate mRNA
decay via Alu elements (Gong and Maquat, 2011), to act as
“sponges” for miRNA binding (Cesana et al., 2011; Tay et al., 2011)
or to enhance translation under stress conditions (Carrieri et al.,
2012). Irrespective of the speciﬁc lncRNA and its function, it is
becoming evident that lncRNAs are organized into independent
“domains” that are required to bind protein complexes. RNA
folding is now believed to provide functional cues to lncRNA
domains, as their primary sequences are poorly conserved. In
addition to domain architecture, lncRNAs can take advantage of the
exquisite feature of nucleic acid base pairing to speciﬁcally select
and modulate target RNA and/or DNA molecules.
Therefore, lncRNAs may work as ﬂexible modular scaffolds that
combine domains engaged for protein-binding with those targeted
to RNA and/or DNA sequences (Guttman and Rinn, 2012).
With this extraordinary amount of data in hand, a large effort is
being devoted to understand the grammar of lncRNAs structure/
function relationship and how their activities integrate into the
biological scenarios the scientiﬁc community has been unveiling in
the last half of the century.
Importantly, lncRNAs and small RNAs present unprecedented
opportunities to modify gene expression at the right time in the
correct space in vivo, providing an almost unlimited reservoir of
new potential pharmacological agents.
RNA-based drugs have the advantage of extending the
druggable genome with high speciﬁcity to all the protein coding
genes as well as to regulatory regions. By taking advantage of
common delivery systems to speciﬁc target organs, nucleic acid-
based therapy may be scalable at a fairly low cost with relatively
common pharmacodynamics and pharmacokinetics properties.
2. Challenges for the molecular therapy of neurodegenerative
diseases
It is fair saying that despite an enormous amount of knowledge
accumulated along the years, the large majority of neurodegener-
ative diseases remain uncurable. A general problem is that the site
of degeneration is not accessible for direct study during life. This is
especially relevant during clinical trials for new therapeutic
treatments since objective measurements of degeneration are
scarce. Importantly, neurodegenerative diseases are characterized
by a long presymptomatic phase during which degeneration is
occurring but no clinical symptoms are evident. Therefore,
potential pharmacological treatments may act only on surviving
cells that cannot provide a sufﬁcient substrate for disease reversal.Please cite this article in press as: S. Gustincich, et al., The Yin and Yang
http://dx.doi.org/10.1016/j.pneurobio.2016.11.001Furthermore, there is still no objective way to make a diagnosis in
presymptomatic phases as well as to monitor disease progres-
sion. In summary, to date no drugs seem to block or even slow the
neurodegenerative process in any of the most socially challenging
neurodegenerative disorders as Alzheimer’s Disease (AD), Parkin-
son’s Disease (PD) and Amyotrophic Lateral Sclerosis (ALS). We still
do not know the initial triggering events of the majority of these
sporadic diseases, limiting our ability to identify a crucial drug
target.
In the case of familial neurodegenerative diseases, genetic
testing can provide the identiﬁcation of patients in the pre-
symptomatic phase. Importanly, it names the triggering cause of
the disease and therefore the main validated drug target. It is
therefore particularly depressing that no treatment is available
even for those diseases such as Huntington’s Disease (HD), where
the cause is precisely deﬁned.
An increasing number of neurodevelopmental disorders with
relatively high prevalence in the general population, including
autism spectrum disorders (1%), schizophrenia (1%), epilepsy
(0.8%) and intellectual disability (2%), have been recently
associated to DNA copy number variations and  in select cases
 to haploinsufﬁciency for speciﬁc genes. Polypeptides encoded by
these genes are extremely heterogenous including molecules
linked to synaptic functions (e.g., NEUREXIN1A, SHANK2, SYNGAP1)
as well as effectors falling in other ontology groups (e.g., enzymes
involved in chromatin dynamics) (Coe et al., 2012; Devlin and
Scherer, 2012; Merikangas et al., 2009; Tam et al., 2009)).
Remarkably, animal models often support the etiological link
between reduced allele dosage and neuro-cognitive symptoms
inferred from human genetics (Etherton et al., 2009; Jiang and
Ehlers, 2013; Nuytens et al., 2013). Gene therapy of neuro-
pathogenic haploinsufﬁciencies is a formidable task. In some cases,
genes can be therapeutically expressed at non-physiological levels
without toxic consequences, e.g. SMN1 in clinical trials for spinal
muscular atrophy (https://clinicaltrials.gov/ct2/show/
NCT02122952) and hamartin in mouse models of tuberous
sclerosis type 1 (Prabhakar et al., 2015). In the majority of cases,
an accurate tuning of gene expression, close to physiological levels,
is strictly required. This is the case of FOXG1, whose hemideletion
and duplication lead to Rett-like and West syndromes, respectively
(Florian et al., 2012). Given the complex control of gene expression,
the somatic delivery of an extra-copy of the disease gene with the
full repertory of regulatory sequences hardly looks a scalable
therapeutic option. On the other hand, the homologous recombi-
nation-based, CRISPR/Cas9-nuclease-assisted correction of gene
deletion in vivo would be equally difﬁcult to implement for three
concurrent key issues: (1) huge size of Cas9-cDNA; (2) length of the
editor DNA, often in the range of megabases; and (3) strong
functional prevalence of non-homologous-end-joining (NHEJ)
machinery over homologous recombination (HR) in neuronal cells
(Orii et al., 2006; Yang et al., 2013). To overcome these limitations,
smaller CRISPR enzymes, deliverable by biosafe AAV vectors, have
been recently discovered (Kleinstiver et al., 2015; Ran et al., 2015).
Furthermore, undesired indels evoked by CRISPR nucleases could
be prevented by transient inhibition of the NHEJ machinery (Chu
et al., 2015; Maruyama et al., 2015). However, the editor DNA issue
is still unﬁxed. Therefore, although CRISPR enzymes are promising
tools for accurate rescue of subtle gene lesions, the vast majority of
neurodevelopmental disorders linked to whole-gene hemidele-
tions remains at present uncurable.
For all neurological diseases requiring genome engineering
and/or correction of gene expression levels, the central nervous
system poses special challenges for therapeutic intervention. First,
it is isolated from the circulatory system by the Blood Brain Barrier
(BBB). While essential nutrients can pass, this vascular gate-
controlling system prevents most molecules from entering the of nucleic acid-based therapy in the brain, Prog. Neurobiol. (2016),
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nucleic acid- and protein-based drugs can be delivered directly
into the brain by intratechal injection into the cerebrospinal ﬂuid
(CSF) or by intranasal administration. Interestingly, it has been
shown that properly functionalized exosomes (Alvarez-Erviti et al.,
2011) and  more recently  selected variants of recombinant AAV
vectors (Deverman et al., 2016) can pass the BBB and effectively
support pan-neural nucleic acid delivery upon intravenous
administration. Most importantly, the brain is composed by a
staggering complexity in neuronal cell types and connectivity that
pose currently insormontable obstacles in delivering the drug
speciﬁcally into the appropriate cell type and in the correct
subcellular or synaptic location.
3. The Yin and Yang of molecular therapy for neurodegenerative
diseases
Manipulating RNA expression in vivo represents a new strategy
for the molecular therapy of neurodegenerative diseases. In this
context, a ﬁrst class of therapeutic drugs should promote down-
regulation of gene expression, in conditions of dominant
neurodegenerative diseases caused by the expression of a
pathological, toxic target gene. Therapeutic molecules have been
developed using technologies based on small antisense oligonu-
cleotides (ASOs) (Gogtay and Sridharan, 2016; Havens and
Hastings, 2016) and small interfering RNAs (siRNAs) (Bobbin and
Rossi, 2016; Lorenzer et al., 2015).
A second equally challenging class of drugs should be based on
RNA molecules that can increase gene expression in vivo.
Augmented levels and/or activity of modiﬁers of pathogenic
pathways may contribute to reestablish a homeostatic cellular
environment. Hijacking the neuroprotective function of neuro-
throphins may represent an attractive strategy to preserve cell
viability and function in diseased brain. Most importantly, for
patients with haploinsufﬁciencies, a therapeutic approach based
on RNA drugs to rescue the physiological amounts of the target
protein would in principle be curative. Unfortunately, no molecules
of this type have been found to date leaving these diseases
untreatable (van Bokhoven, 2011).
This review aims at sharing the excitement over the recent
advancements in the ﬁeld of genomics and on their potential
application in developing new nucleic acid-based therapies for
brain diseases. For the ﬁrst time scientists can use a plethora of
molecular tools to manipulate gene expression in vivo both to
inhibit (Yin) and increase (Yang) the expression of validated drug
target genes. Since the ability to decrease expression has been
within reach for many years, we will brieﬂy describe inhibitory
technologies while focusing on speciﬁc examples in animal
models of neurodegenerative diseases as well as on initial clinical
trials data in humans. Importantly, new technologies are now
developed to increase the expression of selected genes without
permanently modifying host genomes. Here we will focus our
attention on the molecular basis of gene-speciﬁc activation of
transcription (RNAa) and translation (SINEUP). Since these
molecular tools are just at their infancy, no clinical data are
available.
We are concious that an efﬁcient delivery of exogenous nucleic
acids is at the core of drug development. For this matter, we refer
the readers to reviews speciﬁcally addressing this important topic
(some representative reviews cited here) (Gherardini et al., 2014;
Gomes et al., 2015; Kanasty et al., 2013; Liu et al., 2013b; Lorenzer
et al., 2015; Magen and Hornstein, 2014; McConnell et al., 2014;
Reissmann, 2014; Southwell et al., 2012; Zhang et al., 2013).Please cite this article in press as: S. Gustincich, et al., The Yin and Yang
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4.1. Antisense oligonucleotides (ASOs)
Antisense oligonucleotides or ASOs are short, single-stranded
synthetic nucleic acids, tipically 8–50 nucleotides long, that bind
target RNA molecules by standard Watson–Crick base pairing
(Lundin et al., 2015). Upon binding, ASOs modulate target RNA
function. Chemical modiﬁcations are required to achieve ASOs
stability in biological ﬂuids and to increase their potency in binding
their mRNA target. Several variants of ASO chemistry have been
developed aiming at improving nuclease resistance and overall
pharmacokinetic properties (Deleavey and Damha, 2012). In all
cases, primary nucleotide sequence is enriched with a series of
chemical modiﬁcations that overall change nucleic acid biochemi-
cal properties. Chemical modiﬁcations can target the phospho-
diester bond along the nucleic acid backbone (as in
phosphorothioate or PS ASOs, thiophosphoramidate and morpho-
lino ASOs) or the sugar mojety at the 20-position (as in 20-O-methyl
or 2OMe and 20-O-methoxy-ethyl or MOE) (Eckstein, 2014;
Yamamoto et al., 2011). In some cases, modiﬁcations at the sugar
mojety are applied to a portion of the ASO sequence, which is then
combined with an internal unmodiﬁed sequence (as in gapmer
ASOs). Additional variants of ASO chemistry include locked nucleic
acid molecules, or LNO, where the sugar 20-hydroxyl group is
tethered with the 40-carbon atom and tricycle-DNA oligonucleo-
tides (Geny et al., 2016), or tc-DNA, where a conformational
constrain is inserted around C30-C40 and C40-C50 bonds (Goyenvalle
et al., 2015; Renneberg et al., 2002). Most recently, additional
nucleic acid modiﬁcations have been introduced to combine
chemical adducts at the backbone and at the sugars. One class of
such ASOs is provided by peptide nucleic acids, or PNAs, in which
polyamide linkages fully substitute the sugar phosphate backbone
(Wancewicz et al., 2010). PNAs are resistant to degradation but
retain base-pairing capabilities showing enhanced afﬁnity. The
choice of chemical modiﬁcation for ASO design has an impact on
their mechanism of action and speciﬁc ASO chemistry is selected
based on the therapeutic target (Geary et al., 2015).
Therapeutic ASOs work mainly through two mechanisms: 1)
RNAse H-mediated degradation of target RNA; 2) non-degradative
steric block of target RNA (Bennett and Swayze, 2010; Evers et al.,
2015).
ASOs with unmodiﬁed sugars can effectively trigger RNAse H-
mediated degradation of base-paired target mRNAs, thus resulting
in gene silencing. RNAse H speciﬁcally cleaves the RNA mojety
when bound to ASOs in mRNA-DNA heteroduplex. Single-stranded
DNA ASOs are then released from the duplex and made available
for catalyzing degradation of additional mRNA molecules for a
more efﬁcient silencing. This class of ASOs is currently the most
widely used for therapeutic applications. In particular, MOE ASO
gapmers targeting mutant SOD1 are the ﬁrst example of ASOs
tested in human clinical trial to treat patients with ALS (Miller
et al., 2013).
Chemical modiﬁcations at 20 position of sugars render ASOs and
paired RNAs resistant to RNAse H-mediated degradation. While
hampering degradation mechanism, 20 modiﬁcations provide
enhanced stability, better pharmacokinetic properties and, most
importantly, increased binding to target RNA. Non-degradative
ASOs act by creating a steric hindrance that blocks target RNA from
further processing and therefore inhibits its function. In most
cases, non-degradative ASOs negatively regulate mRNA transla-
tion, blocking the recognition of target mRNA by the ribosomes and
ultimately down-regulating gene expression. of nucleic acid-based therapy in the brain, Prog. Neurobiol. (2016),
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It collectively refers to a large array of natural regulatory
processes, conserved from yeast to humans, where endogenous
molecular machineries, programmable by small-sized RNAs,
negatively regulate gene expression (Bobbin and Rossi, 2016).
Three types of small RNAs are involved in RNAi, siRNAs,
microRNAs (miRNAs) and Piwi-interacting RNAs (piRNAs). siRNAs
derive from Dicer-dependent processing of dsRNAs, in turn
originating from convergent transcription, bidirectional transpo-
son readthrough or unidirectional transcription of inverted repeats
(Elbashir et al., 2001; Fire et al., 1998). miRNAs are generated by
processing of long primary transcripts (pri-miRNAs), along the
classical Drosha/Dicer pathway or the splicing-machinery-medi-
ated mirtron pathway (Ha and Kim, 2014; Lee et al., 1993). piRNA,
still poorly characterized in mammals, are produced in Drosophila
via Zucchini-mediated parsing of long primary transcripts and
their subsequent trimming, and may be ampliﬁed thanks to a ping-
pong cycle catalized by Vasa, Piwi/Aub and Ago3 (Brennecke et al.,
2007; Vagin et al., 2006).
miRNAs and siRNAs are loaded onto RNA-instructed silencing
complexes (RISCs), which prevalently act at post-transcriptional
level (Agrawal et al., 2003). RISC-mediated silencing may be
achieved by straight target-RNA cleavage. This usually occurs upon
perfect matching between the siRNA guide included in the RISC
complex and its target, and requires the endonucleolytic activity of
the Ago2 RISC subunit. Conversely, prevalently in case of miRNA-
programmed RISCs, Agos recruit GW182, which in turn conveys to
RISC other silencing machineries. The interaction of GW182 with
poly(A)-binding protein (PABP) may displace PABP, leading to
destabilization of the target mRNA and decrease of its translation.
Furthermore, GW182 may recruit deadenylases and the decapping
complex via a CCR4–NOT complex bridge, further destabilizing the
target mRNA and jeopardizing its translation. As for piRNAs, they
are loaded onto different RISCs, which are imported into the
nucleus and act co-transcriptionally. In these cases, target
recognition recruits silencing factors and chromatin modiﬁers
increasing local levels of H3K9me3 and leading to transcriptional
silencing (Iwasaki et al., 2015).
Endogenous molecular machineries supporting siRNA- and
miRNA-RNAi have been extensively exploited to achieve artiﬁcial
RNAi for therapeutic applications (Bobbin and Rossi, 2016; Lam et al.,
2015).Whiledifferenttypesof exogenousRNAshave been employed,
immature RNA precursors have been often shown to outperform
their small RNA derivatives. Among the best performing effectors
there are 29-bp long ds-siRNA precursors as well as hairpin RNA
precursors (small hairpin RNAs or shRNAs), based on backbones of
endogenous pri-miRNAs. These effectors may be delivered to target
cells as pre-made molecules, with appropriate chemical modiﬁca-
tions to stabilize them and promote their processing (Deleavey and
Damha, 2012; Lam et al., 2015). Alternatively they may be delivered
as DNApolII- or DNApolIII-dependent, cDNA-encoding transgenes to
achieve a more persistent effect (Lorenzer et al., 2015). Lentiviral and
adeno-associated viral vectors are the most commonly used to
deliver shRNAs and miRNAs into the brain, as they provide stable
expression while being poorly immunogenic, replication incompe-
tent and safe (Keiser et al., 2016). Recently, great therapeutic
potentials are held by engineered versions of adeno-associated
vectors that are capable of crossing the blood brain barrier and
efﬁciently deliver transgenes into the brain even after a single
intravenous injection (Deverman et al., 2016).
4.3. Anti-miRNA oligonucleotides (or antagoMIR or blockmir)
miRNA expression and function has been proved altered in a
number of human disorders, such as cancer, autoimmune diseasesPlease cite this article in press as: S. Gustincich, et al., The Yin and Yang
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increasing interest in developing therapeutic strategies to inhibit
miRNAs in disease conditions. Moreover, therapeutic miRNA
targeting has the advantage that a single miRNA-drug can affect
many target genes simoultaneuosly, ultimately affecting the whole
disease pathway. Three main strategies have been adopted to
achieve down-regulation of miRNA activities: expression of miRNA
sponges, small molecule inhibitors of miRNAs and anti-miRNA
ASOs. In the ﬁrst case, expression of long coding or non-coding
transcripts containing multiple copies of miRNA binding sites can
act as sponges that compete with natural targets and reduce the
actual concentration of active miRNAs. This strategy has been
based on recent discoveries that lncRNAs (lincRNAs and pseudo-
genes) can act as natural miRNA sponges (Cesana et al., 2011; Tay
et al., 2011). Currently, the use of miRNA sponges has been limited
to in vitro applications and some pre-clinical mouse models (Ebert
and Sharp, 2010). Circular RNAs, referred to as circRNAs, are a novel
class of abundant, nuclease-resistant lncRNAs that are generated
by covalent link of 50 and 30 termini (Memczak et al., 2013; Salzman
et al., 2012). circRNAs can compete with protein-coding mRNAs
and lncRNAs and act as sponges for miRNAs (Hansen et al., 2013).
As an example, CiRS-7 has been shown to adsorb miR-7, thus
releasing its target mRNAs, including Parkinson’s disease-associ-
ated a-synuclein, from inhibition (Hansen et al., 2013; Lukiw,
2013; Salzman, 2016). Furthermore, from compound libraries
screenings small molecules have been identiﬁed for their
inhibition of the expression of speciﬁc miRNAs (Young et al.,
2010). However, their therapeutic use is yet limited because of high
IC50 and poor speciﬁcity. Finally, wider therapeutic application is
coming from the use of ASOs to speciﬁcally target selected miRNAs
thus blocking their function. Anti-miRNA oligonucleotides, or
antagoMIR or blockmir, are single-stranded ASOs that tightly bind
miRNAs and inhibit their activity on the target mRNA(s). Many
antagoMIRs targeting different miRNAs are currently being
developed for hepatitis C virus infection, liver cancer, heart failure
and metabolic disorders of the heart (Li and Rana, 2014). Some of
them have already reached the clinic for phase I/II testing. For
neurodegenerative disorders, antagoMIRs have been used in
mouse models of AD and ALS (see below).
5. The Yin side of nucleic acid-based therapy: applications to
neurodegenerative diseases
5.1. Alzheimer’s disease
Alzheimer’s Disease (AD) is the most common neurodegenera-
tive disorder, affecting nearly 44 million people worldwide and
accounting for 60–80% of all forms of dementias. AD neuropathol-
ogy is characterized by the deposition of insoluble aggregates of
beta-amyloid (Ab) and tau in extracellular plaques and intracellu-
lar neuroﬁbrillary tangles, resulting in progressive neuronal loss
and cortical atrophy. AD patients suffer from progressive cognitive
impairment, gradual loss of memory and learning capabilities,
ultimately leading to degeneration of the overall quality of life
(Scheltens et al., 2016). Although the precise mechanisms that lead
to AD are not fully understood, several studies indicate that
processing of amyloid precursor protein (APP) has a key role in the
disease. b-amyloid precursor protein cleaving enzyme 1 (BACE1) is
involved in APP processing giving rise to Ab fragments. Increased
BACE1 activity has been observed in AD and associated to
neurodegeneration and accumulation of Ab aggregates. Thus,
inactivation of BACE1 is considered a potential therapeutic strategy
to treat AD. To this purpose, lentiviral vectors were used to deliver
BACE1-targeting siRNAs into hippocampus of APP transgenic mice.
Upon injection, siRNAs lowered levels of BACE1, reduced amyloid
production and rescued neurodegeneration and behavioural of nucleic acid-based therapy in the brain, Prog. Neurobiol. (2016),
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BACE1-speciﬁc siRNAs were delivered to the mouse brain by
systemic injection of modiﬁed exosomes, containing neuron-
speciﬁc RVG peptide fused to Lamp2b exosomal protein (Alvarez-
Erviti et al., 2011). BACE1-siRNA loaded exososomes induced a
strong down-regulation of BACE1 mRNA (60%) and protein (62%) in
wt mice, thus demonstrating their efﬁcacy as brain delivery
system. Synthetic miRNAs were also used to decrease BACE1 levels
and rescue disease phenotype in AD mouse model upon surgical
delivery through Adeno-associated viral particles (Piedrahita et al.,
2015).
BACE1 mRNA is positively regulated by an antisense lncRNA,
named BACE1-AS (Faghihi et al., 2008). Interestingly, BACE1-AS is
upregulated in brain samples from AD patients thus becaming
itself a target for siRNA strategies for AD. Indeed, knockdown of
either one of BACE1 or BACE1-AS transcripts by intra-ventricular
infusion of modiﬁed siRNAs caused concordant downregulation of
both transcripts in APP transgenic mice, ultimately leading to
reduced Ab production and plaque deposition (Modarresi et al.,
2011).
In addition to siRNA-based strategies, ASOs are also employed
to reduce expression of proteins involved in AD pathogenesis. ASOs
targeting acetylcholinesterase, mutated APP as well as PSEN1 had
shown promising effects in transgenic AD models (Chauhan and
Siegel, 2007; Farr et al., 2014; Fiorini et al., 2013).
Finally, antagoMIR strategies are also under study as potential
therapeutics for AD. Expression of several miRNAs is dysregulated
in AD brains, resulting in alteration of molecular targets and
pathways known to be associated to AD pathology (Di Meco and
Pratico, 2016). BACE1 mRNA, whose quantity is elevated in AD, is a
direct target of miR-188-3p, that conversely is down-regulated in
the brain of AD mice. Overexpression of miR-188-3p by intracranial
viral delivery reduced BACE1 levels, decreased amyloid inclusions
and improved synaptic activity and cognitive functions (Zhang
et al., 2014).
5.2. Amyotrophic lateral sclerosis
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative
disorder characterized by the selective loss of motor neurons in the
spinal cord and brain. ALS patients suffer from muscle stiffness and
severe muscle weakness. They ultimately die by respiratory failure.
The progression of ALS is rapid and most patients survive only 3–5
years after diagnosis. The most advanced antisense approach to
treat ALS is based on ASOs targeting Superoxide Dismutase 1
(SOD1), a protein mutated in familial cases of the disease. Selection
of SOD1-speciﬁc ASOs, optimization of delivery and efﬁcacy of
treatment were evaluated in a rat model expressing human
mutated SOD1 (SODG93A). SOD1-ASOs were injected intro cerebral
ventricles and proved to reach the spinal cord circulating through
the cerebrospinal ﬂuid. ASO-treated mice showed decrease levels
of SOD1 protein and mRNA throughout the brain and spinal cord.
When ASO infusion was performed before disease onset,
transgenic rats displayed slower disease progression and increased
survival (+37%) (Smith et al., 2006).
Following encouraging pre-clinical data, the ﬁrst phase-1
clinical trial was funded to test safety, tolerability and pharmaco-
kinetics of ASO treatment targeting SOD1 upon intrathecal
administration in patients with SOD1 mutation (patients with
different types of SOD1 mutation were enrolled in this study).
Cerebrospinal ﬂuid samples taken immediately after infusion
indicated the presence of the drug. Analysis of spinal cord samples
taken from one participant who later died from ALS indicated: i)
higher ASO levels at the site of injection as compared to distant
sites; ii) proper estimate of drug persistence in the body (peak
concentration at 12 h after infusion and lowered to basal level atPlease cite this article in press as: S. Gustincich, et al., The Yin and Yang
http://dx.doi.org/10.1016/j.pneurobio.2016.11.00124 h). Overall, a 15% variation in SOD1 levels in the cerebrospinal
ﬂuid was observed, predicting that higher doses of the drugs are
needed to achieve effective down-regulation (Miller et al., 2013).
Additional antisense strategies are also being developed in
SODG93A animal models using siRNAs. Several studies have
demonstrated effectiveness of SOD1 silencing approach in mouse
models of ALS, proving reduced SOD1 expression, improved motor
neuron survival, and delayed onset of ALS symptoms in treated
animals (Nizzardo et al., 2012). In most cases, silencing RNAs are
delivered as shRNA precursors using viral vectors.
Most recently, it has been shown that miR-155 is increased in
SODG93A mice as well as in the spinal cord of ALS patients, thus
providing a new therapeutic target. Indeed, antisense oligonucle-
otide therapy devised to inhibit miR-155 (antagoMIR) was
developed and tested in mice. After continuous intra-ventricular
administration, treated mice showed extended survival and
prolongued disease duration (38%) (Koval et al., 2013). Therapeutic
potential of antagoMIR for miR-155 in ALS was further validated in
a more recent study, where genetic ablation of miR-155 in SODG93A
transgenic mice restored molecular signatures in the periphery
(monocyte signature) and in the central nervous system (microglia
signature), as determined by proteomics and transcriptomics
(Butovsky et al., 2015). Finally, intra-ventricular delivery of LNA
formulation of anti-miR-155 molecule delayed disease onset and
extended survival in SOD1 mice (Butovsky et al., 2015). The exact
molecular targets of anti-miR-155 therapy have yet to be
identiﬁed.
5.3. Amyotrophic lateral Sclerosis/Frontotemporal dementia
Expanded hexanucleotide repeats in the ﬁrst intron of C9orf72
gene were recently identiﬁed as the most common genetic cause of
ALS, FrontoTemporal Dementia (FTD) or concomitant ALS/FTD.
Although the exact mechanisms by which repeated elements cause
neurodegeneration are currently unknown, recent studies suggest
that neurodegeneration by C9orf72 is mediated by RNA toxicity,
loss of C9orf72 gene functions or, possibly, a combination of both.
As support to this hypothesis, RNA foci are present in ALS/FTD
brains. Expanded RNA is involved in repeat-associated non-ATG
(RAN) translation that produces aberrant peptides or dipeptides
polymers. Recently, three independent studies reported the use of
antisense oligonucleotides technology to modulate C9orf72
expression and RNA foci (Donnelly et al., 2013; Lagier-Tourenne
et al., 2013; Sareen et al., 2013). ASOs were designed to target the
sequences upstream or downstream the toxic repeat expansion. In
all cases, a more pronounced down-regulation of C9orf72 was
obtained with down-stream targeting ASOs. ASOs were tested in
patients’ ﬁbroblast, patients-derived iPS cells and iPS-differentiat-
ed to motor neurons. ASOs mediated therapy was able to efﬁciently
target C9orf72 transcript suppressing RNA foci formation and
reversing gene expression alterations observed in patients cells.
The positive effect on RNA foci could be obtained with ASOs that
down-regulate overall C9orf72 levels, targeting intronic regions, as
well as with those that speciﬁcally hybridize to transcripts
containing the exanucleotide repeat expansion. The use of
sense-speciﬁc ASOs could not correct RNA signature in patients’
ﬁbroblasts indicating that antisense-speciﬁc ASOs were probably
required for therapeutic effects. Interestingly, siRNA molecules
targeting C9orf72 were also tested and surprisingly proved
uneffective.
Finally, in Lagier-Tourenne et al. (Lagier-Tourenne et al., 2013), a
proof of principle study was performed in vivo by delivering
C9orf72-speciﬁc ASOs in the mouse brain with intracerebroven-
tricular stereotaxic injection. Prolonged down-regulation of
C9orf72 was observed. Microarray analysis revealed tolerability
of ASO injection in vivo, with small changes in overall expression of nucleic acid-based therapy in the brain, Prog. Neurobiol. (2016),
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no neuropathological or behavioural defects.
Several studies are ongoing to better deﬁne the genetic features
of c9orf72-related pathology in patients in order to prepare for
future clinical trials targeting this gene.
5.4. Tauopaties
In AD, progressive supranuclear palsy and in a number of other
neurodegenerative diseases collectively known as tauopathies, the
macrotubule-associated protein tau becomes hyperphosphory-
lated and aggregates to form intracellular neuroﬁbrillary tangles
(Iqbal et al., 2016; Wang and Mandelkow, 2016). Antisense
oligonucleotide strategies have been developed to down-regulate
tau expression and reduce tau-associated seizures in mice. In a ﬁrst
study, injection of tau-speciﬁc ASOs directly into the cerebrospinal
ﬂuid reduced levels of endogenous murine tau throughout the
entire central nervous system and cerebrospinal ﬂuid. Down-
regulation of tau had no effect on baseline motor or cognitive
behavior, but was associated to reduced seizures in chemically-
induced seizures model (DeVos et al., 2013). More recently,
additional ASOs were designed to target human tau and tested in
human neuroblastoma cell lines and in transgenic mice expressing
human tau. The strongest effect was achieved with ASOs targeting
splice sites, thus mediating exon skipping and inducing frame-
shifts and premature stop codon, with subsequent mRNA
degradation (Sud et al., 2014). siRNAs were also employed to
silence Tau levels and rescue disease phenotype in vivo in
transgenic mice expressing mutated human tau (Xu et al., 2014).
Recently, expression proﬁling studies have revealed altered
quantities of miRNAs in AD and age-related tauopathies (Qiu
et al., 2015), implying their role in pathogenesis. As a consequence,
therapeutic modulation of miRNAs is expected to have an impact
on pathways implicated in the disease. miR-129 was identiﬁed to
be downregulated in brain tissues from patients with AD and
taupathies (Santa-Maria et al., 2015). By in vitro experiments, miR-
129 was found to bind directly the 30UTR of tau mRNA. In vivo,
overexpression of miR-129 silenced tau protein and partially
abrogated tau toxic effect in a Drosophila model producing human
tau. In another study, intra-brain delivery of miR-132 mimics via
osmotic pumps resulted in the reduction of tau and amelioration of
long-term memory in an AD mouse model (Smith et al., 2015).
5.5. Parkinson’s disease
Several genetic evidences indicate that a-synuclein expression
affects PD onset, severity and risk. Increased expression of
a-synuclein provokes a series of events altering neuronal
homeostasis and ultimately cell death. While a-synuclein is prone
to aggregation as the crucial component of Lewy Bodies, the gene
has been found mutated in rare familial cases. Importantly,
a-synuclein gene triplication (Farrer et al., 2004; Sekine et al.,
2010; Singleton et al., 2003) and duplication (Chartier-Harlin et al.,
2004; Ibanez et al., 2004; Nishioka et al., 2009) promote early-
onset PD, proving that a higher level of wild type a-synuclein can
lead to pathogenesis (Devine et al., 2011). In this context, genetic
variants in its promoter region are associated to sporadic PD cases
with lower expression being beneﬁcial (Chiba-Falek and Nuss-
baum, 2001). Recent reports support the hypothesis that
a-synuclein also plays a critical role in propagating the neurode-
generative process via prion-like mechanisms. Therefore, thera-
peutic strategies aiming at inhibiting its cellular function and
expression are under intense scrutiny to achieve disease amelio-
ration.
A large effort is undergoing in optimizing siRNA- and ASO-
based drugs to target a-synuclein mRNA. Widespread delivery intoPlease cite this article in press as: S. Gustincich, et al., The Yin and Yang
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peptide (RGV) to extra-exosomal N-terminus of Lamp2b protein
(Cooper et al., 2014). In normal mice, systemic administration of
siRNA-loaded RGV-exosomes decreased a-synuclein mRNA and
protein to 40–50% of its endogenous levels in Substantia Nigra,
Striatum and cortex. Most importantly, in transgenic mice
expressing human phospho-mimic S129D a-synuclein, treatment
with RSV-exosome-siRNAs reduced aggregated and insoluble
proteins in midbrain dopaminergic neurons.
More recently, down-regulation of a-synuclein expression was
obtained using recombinant adeno-associated virus to deliver
a-synuclein-speciﬁc shRNA in the Substantia Nigra in normal rats
(Zharikov et al., 2015). Under physiological conditions, a 35%
reduction of mRNA and protein levels did not cause any motor
deﬁcit or neuronal degeneration. However, when rats were
subjected to chemical mitochondria intoxication, mimicking PD-
like symptoms, AAV-shRNA targeting a-synuclein proved to be
neuroprotective, safeguarding dopaminergic neurons in the
Substantia Nigra and dopaminergic terminals in the Striatum
while rescuing motor functions.
5.6. Huntington’s disease
Huntington disease (HD) is an inherited, autosomal dominant,
fatal neurodegenerative disorder caused by a CAG repeat expan-
sion in the ﬁrst exon of the gene encoding for huntingtin (HTT)
protein. Pathogenic expansion of CAG sequence is translated into
an elongated stretch of polyglutamines (polyQ) at the N-terminal
of HTT protein, resulting in the production of a mutant protein. The
mutant protein is toxic and causes neuronal dysfunction and
degeneration leading to motor symptoms, cognitive decline and
psychiatric disturbances (Andrew et al., 1993; The Huntington’s
Disease Collaborative Research Group,1993). Silencing mutant HTT
using nucleic acids would eliminate the basis of HD pathology.
However, these approaches have raised some concerns about
possible side effects due to the diminishment of HTT physiological
functions. Indeed, constitutive loss of wt allele is lethal in mouse
embryos and reduced expression leads to neurodegenerative-like
phenotypes (Dragatsis et al., 2000; Duyao et al.,1995), while recent
data seem to indicate that ablation of HTT in adult neurons is
nondeleterious (Wang et al., 2016). Extensive body of research has
demonstrated that wt HTT is neuroprotective and plays funda-
mental roles in several cellular pathways (Saudou and Humbert,
2016). As a consequence, in addition to nonallele-selective
silencing approaches, novel strategies are being developed aimed
at allele-speciﬁc suppression of mutant HTT (Beaudet and Meng,
2016; Keiser et al., 2016). Nucleic acid-based therapeutic strategies,
using ASOs and RNAi, hold great promise. Indeed, several
preclinical studies have demonstrated the utility of such strategies
to improve HD neuropathology and symptoms. Initial studies in
patients-derived cells lines indicated selective inhibition of HTT
protein expression by double-stranded and single-stranded ASOs
(Hu et al., 2009). In mouse models, a sustained therapeutic reversal
of HD pathology was obtained by transient repression of HTT
synthesis using HTT-targeting ASOs (Kordasiewicz et al., 2012).
Transient infusion of HTT-ASOs into the cerebrospinal ﬂuid of
symptomatic HD mouse models effectively suppressed HTT mRNA
and protein levels and mutant HTT accumulation, causing delayed
disease progression and reversal of disease phenotype. Similar ASO
infusion into nonhuman primates showed effective reduction of
HTT protein in several brain regions (Kordasiewicz et al., 2012).
Additional studies described selective down-regulation of mutant
HTT by allele-speciﬁc and single-nucleotide polymorphism-
speciﬁc ASOs (Carroll et al., 2011; Kay et al., 2015; Ostergaard
et al., 2013; Southwell et al., 2014). of nucleic acid-based therapy in the brain, Prog. Neurobiol. (2016),
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transcriptional level is the use of siRNAs to trigger the RNAi
pathway. Initial studies using RNAi as a therapeutic strategy
enabled the reduction of HTT mRNA and protein in vitro in cellular
models of HD (Chen et al., 2005). Subsequently, RNAi-based
approach was applied in vivo in preclinical trial for HD (Harper
et al., 2005). Single bilateral injections of AAV delivering anti-HTT
shRNA were administered into the striatum of HD transgenic mice.
Signiﬁcant reductions in mutant HTT mRNA levels (approximately
55%) were observed, accompanied by a reduction of HTT inclusions
and recovery of motor deﬁcits. Several other preclinical studies
followed in the most recent years, mainly focusing on siRNA
delivery systems using nanoparticles or cholesterol-conjugated
molecules and adeno-associated vectors (Aronin and DiFiglia,
2014; Keiser et al., 2016). Nonallele-speciﬁc silencing by RNAi
proved to be well-tolerated resulting in long-lasting amelioration
of neuropathological deﬁcits in mice (Boudreau et al., 2009; Drouet
et al., 2009; Dufour et al., 2014) and non-human primates (Grondin
et al., 2015; McBride et al., 2011). Selective silencing of mutant HTT
was achieved with siRNAs (Pﬁster et al., 2009) and artiﬁcal miRNAs
(Monteys et al., 2015) targeting allele-speciﬁc polymorphisms.
Allele-selective silencing was also demonstrated in patients’ cells
and in mouse models with single-stranded antisense oligonucleo-
tides (ss-siRNAs), that combine simplicity of ASO technology with
the efﬁciency of RNAi (Yu et al., 2012). Finally, the development of
new-generation of brain-targeting adeno-associated viral vectors
represents a promising platform for silencing therapy in neurode-
generative disorders (Choudhury et al., 2016; Deverman et al.,
2016). In mice, a single intravenous injection of modiﬁed AAV
encoding an artiﬁcial miRNA was sufﬁcient to induce effective
silencing of HTT in the brain (Choudhury et al., 2016).
Nonallele-speciﬁc HTT silencing approach for HD using ASO
technology has recently entered the clinic with a phase1/2 trial
(source ClinicalTrial.gov, 2015). Together with safety, its aim will
include measuring the level of mutant huntingtin protein in the
cerebrospinal ﬂuid using a newly developed assay (Southwell et al.,
2015; Wild et al., 2015).
5.7. Transthyretin familial amyloid polyneuropathy
Transthyretin familial amyloid polyneuropathy (TTR-FAP) is an
autosomal dominant inherited disease, characterized by progres-
sive neuropathy and cardiomyopathy. Like other forms of TTR
amyloidosis, TTR-FAP is caused by mutations in the gene encoding
for transthyretin (TTR). Val30Met is the most common mutation in
TTR-FAP patients and accounts for 50% of TTR-FAP cases worldwide
(Gertz et al., 2015; Parman et al., 2016). Mutated TTR has the
propensity to misfold into insoluble and pathologic amyloid ﬁbrils.
These form extracellular deposits that accumulate in the periph-
eral and central nervous system as well as in the heart, giving rise
to the clinical manifestations (Sipe et al., 2014). As such, reducing
the quantities of TTR deposits is crucial for therapeutic treatment
of TTR-FAP. A siRNA-based drug targeting TTR and delivered by
means of lipid nanoparticles is in clinical trial for TTR-FAP. Data
from phase II study demonstrate a robust knockdown of serum TTR
protein with >80% reduction after two doses. Multiple doses were
generally safe and well tolerated (Suhr et al., 2015). A randomized,
placebo-controlled, double-blind phase III study (APOLLO,
NCT01960348) is currently ongoing for TTR-FAP patients with
Val30Met to evaluate the safety and efﬁcacy of TTR-targeted siRNA
therapy. Additional siRNA sequences and delivery methods are still
under development. Preclinical testing indicate that RNAi-medi-
ated knockdown of TTR can efﬁciently reduce toxic deposition
across a broad range of affected tissues in a mouse model of TTR-
FAP (Butler et al., 2016).Please cite this article in press as: S. Gustincich, et al., The Yin and Yang
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6.1. Modiﬁed mRNA technology
Modiﬁed mRNA technology has recently emerged as a novel
option to gene therapy approach. The use of DNA and mRNA as
genetic source of therapeutic proteins has started decades ago, but
only the advent of novel chemistry to stabilize mRNA molecules
has prompted the use of mRNA-based therapy to pre-clinical and
clinical settings (Sahin et al., 2014). By deﬁnition, mRNA has the
potential to produce proteins and peptides of therapeutic interest
with easy scalability in the number of targets. mRNA-based
therapeutics display several advantages over other nucleic acid
strategies: i) delivered mRNA does not need to enter the nucleus to
be functional; ii) mRNA does not integrate into the genome; iii)
production is relatively simple and inexpensive. However, since
recent years, there have been two major problems associated to
mRNA therapeutics: i) mRNA is highly unstable in cells and in vivo
to achieve sufﬁcient protein expression and ii) mRNA induces
strong immune responses in the host organism, thus hampering
repeated administrations. A variety of formulations have been
developed to protect nucleic acids from extracellular degradation
by RNAses, to facilitate cellular uptake and enable endosomal
escape and easy release into the cytoplasm. Nanosized particles are
typically employed with different biochemical and biophysical
properties: positively charged lipids, cationic polypetides, poly-
mers and micelles (Cheng and Lee, 2016; Li et al., 2016a; Reichmuth
et al., 2016; Uchida et al., 2013). Overall, lipid nanoparticles and
polyplex nanomicelles are the most widely used for therapeutic
mRNA delivery in vivo and in clinical trials (Reichmuth et al., 2016;
Sahin et al., 2014).
Chemically-modiﬁed mRNA synthesized in vitro and combined
with naturally occurring modiﬁed ribonucleotides has been
employed to overcome the aforementioned obstacles and has
shown a great promise as therapeutic tool for gene therapy.
Expression of recombinant proteins after delivery of chemically
modiﬁed mRNA has been shown to be effective in mice and non-
human primates in models of anemia, congenital lung disease and
myocardial infarction (Kariko et al., 2012; Kormann et al., 2011;
Zangi et al., 2013). Modiﬁed mRNA is currently in clinical trails as
cancer immunotherapy and vaccine (Kallen and Thess, 2014).
Alternatively, unmodiﬁed mRNA has been sequence-engineered to
display higher stability and translatability when introduced in vivo
in complexed nanoparticles for vaccines (Kubler et al., 2015; Petsch
et al., 2012; Schnee et al., 2016) and therapy in the brain (Lin et al.,
2016; Nabhan et al., 2016). Recently, unmodiﬁed mRNA encoding
for erythropoietin has been proven effective in large animals
(Thess et al., 2015).
6.2. AntagoNATs
Inhibition of natural AS lncRNA transcripts (or natural antisense
transcripts or NAT) can be used as an indirect mean to modulate
endogenous sense mRNA levels. To speciﬁcally inhibit NATs,
Wahlested and collaborators took advantage of the antisense
oligonucleotide chemistry to develop AntagoNATs. AntagoNATs are
ASOs that inhibit a regulatory antisense lncRNA, thus indirectly
modulating sense gene expression. AntagoNATs are designed to
target S/AS overlapping region, thus blocking AS function mainly
through RNAse H-mediated degradation (Wahlestedt, 2013).
Depending on NAT function, AntagoNATs can be used for down-
regulating gene expression, as for BACE1-AS (Faghihi et al., 2008;
Modarresi et al., 2011), or for up-regulation, as for BDNF-AS
(Modarresi et al., 2012) and SCNA1 (Hsiao et al., 2016). of nucleic acid-based therapy in the brain, Prog. Neurobiol. (2016),
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The binding capabilities of non-degradative ASOs have also
been employed for up-regulating gene expression. Mechanistically
this can be obtained by blocking mRNA degradation or by
increasing mRNA transcription. ASOs designed to bind miRNAs
(referred to as antagoMIR or blockmir) increase mRNA stability
interfering with miRNA-mediated mRNA degradation pathway and
ultimately leading to enhanced accumulation of protein products
(Li and Rana, 2014). Up-regulation of gene expression can also be
obtained by ASOs designed to bind AS lncRNAs involved in
chromatin remodeling. In this context, a class of AS lncRNAs is
required for suppressing gene expression by recruiting compo-
nents of the Polycomb Repressor Complex 2 (PRC2) to the gene
locus from which they are transcribed. ASO binding to lncRNA can
therefore block PRC2 complex assembly allowing transcription to
restart, thus inducing up-regulation of sense protein-coding mRNA
present at the same locus (Zhao et al., 2010).
Alternatively, ASOs that do not degrade target mRNAs can be
designed to modulate their processing. When targeting pre-
mRNAs, ASOs can modulate splicing and are referred to as exon-
skipping ASOs or splice-switching oligonucleotides (SSOs)
(Havens and Hastings, 2016). SSOs are designed to interfere with
RNA sequences required for the splicing machinery thus
inhibiting pre-mRNA interaction with the spliceosome including
small nuclear RNAs and splicing factors. As a result, SSOs can
repair defective splicing, promote exon-skipping or induce exon-
retention, thus restoring the production of a functionally
corrected protein. SSOs are usually synthesized using LNA or
PNA chemistry to avoid target RNA degradation and achieve
potent binding. SSOs have been used in the clinic for the
treatment of Duchenne Muscolar Dystrophy (Hodgkinson et al.,
2016; Kole and Krieg, 2015; Mendell et al., 2016). In the context of
neurodegenerative disorders, therapeutic SSOs have been
designed to target ATM in Ataxia Telangectasia (Du et al., 2011,
2007), SMN2 in Spinal Muscolar Atrophy (see below) and
microtubule associated protein Tau in Frontotemporal Dementia
and Parkinsonism linked to chromosome 17 (FTDP-17) (Peacey
et al., 2012). A state-of-the-art description of the use of ASOs as
splicing modiﬁers can be found elsewhere (Havens and Hastings,
2016; Kole et al., 2012; Rigo et al., 2014; Siva et al., 2014).
6.4. RNA activation (RNAa)
6.4.1. Historical and operational features
The ﬁrst report of transcriptional stimulation by small RNAs,
brieﬂy RNA activation (RNAa), dates back to 2006, when Li et al. (Li
et al., 2006) showed that siRNA-like molecules targeting the
promoters of three genes of oncological interest, Cadherin E,
p21WAF1/CIP1 and VEGF, were able to elicit a speciﬁc and prolonged
stimulation of their transcription in human cells. Since then a
plethora of similar reports corroborated these early ﬁndings,
pointing to RNAa as a pervasive phenomenon (Faghihi et al., 2010),
that is potentially implicated in endogenous regulation of
transcription and of great interest for therapy. Currently we still
have limited understanding of its molecular mechanisms. Despite
their likely mechanistic heterogeneity, RNAa processes share a
well-deﬁned set of phenomenological traits.
First, different types of small activating RNAs (saRNAs) may
trigger RNAa. They include siRNA-precursor-like 21nt-dsRNAs (Li
et al., 2006), pre-miRNA-like shRNAs (Turunen et al., 2009) and
pri-miRNA-like molecules (Diodato et al., 2013). Albeit not
necessary, speciﬁc covalent modiﬁcations may enhance their
activity (Kang et al., 2012; Matsui et al., 2010; Place et al., 2010,
2012). Effective saRNAs are usually directed against Transcription
Start Site (TSS) (Li et al., 2006; Schwartz et al., 2008) or polyA-sitePlease cite this article in press as: S. Gustincich, et al., The Yin and Yang
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modules regulating gene-of-interest (GOI) transcription (Diodato
et al., 2013) and the transcribed region of the gene (Liu et al.,
2013a). They may be both sense- and antisense-oriented (Diodato
et al., 2013). Importantly, ﬁne location of the saRNA-target often is
a key issue since shifting it by only a few bases can dramatically
affect its outcome. Mismatches between the saRNA and its target
may be tolerated, however only if far from saRNA 50 end (Li et al.,
2006).
Gene responsivity to small RNAs depends in complex ways on
the differentiative state of cells and on the functional state of the
target gene. In some cases, low basal expression of this gene may
predispose to transactivation (Yue et al., 2010). In other cases,
RNAa is restricted to cells and tissues expressing the target gene
(Diodato et al., 2013; Li et al., 2006). In these latter cases,
generalized delivery of aRNAs might be employed to stimulate
selective expression of defective genes within their expression
domain with no risks of ectopic activation.
When compared to RNAi, RNAa often displays a later onset,
usually with a delay of 24–48 h (Place et al., 2010), and it lasts quite
longer since one unique saRNA delivery may exert an effect
prolonged over >7 days (Li et al., 2006; Place et al., 2010).
Finally, mRNA-upregulation achieved via RNAa is usually within
physiological range (often <5-folds) This is important since subtle
changes of target mRNA levels may deeply impact the functional
state of the cell, giving rise to predictable and overt biological
effects (Diodato et al., 2013; Janowski et al., 2007; Voutila et al.,
2012).
Until now, many genes of oncological and cardio-vascular
interest have been upregulated by RNAa for purposes of
experimental therapy. In this respect, RNAa-mediated gene
stimulation is of obvious therapeutic interest for dozens of
different hemizygous gene deletions at the basis of a wide
spectrum of neuropathological conditions, including epilepsy,
mental retardation, autism, schizophrenia and neurodegenera-
tion (Lal et al., 2015; Lee et al., 2015). Furthermore, upregulation
of speciﬁc endogenous genes may help counteracting conse-
quences of trauma and neurodegeneration (Modarresi et al.,
2012).
6.4.2. Molecular mechanisms
We are still far from full understanding of RNAa dynamics.
Experimental data suggest that RNAa is a heterogeneous process
and at least two classes of molecular mechanisms may underlie it.
RNAa may take place via post-transcriptional/co-transcriptional
downregulation of AS-transcripts in charge of limiting S-transcript
expression. Alternatively, saRNAs may convey supramolecular
complexes stimulating transcription to target chromatin.
6.4.3. Downregulating AS transcripts in charge of inhibiting sense
transcript expression
As described previously, the large majority of sense mRNAs
presents antisense transcription (Katayama et al., 2005). In some
cases, antisense RNAs can inhibit transcription of its sense gene
and saRNAs can then function by downregulating the anticorre-
lated, antisense companion of the transcript they promote. This
phenomenon has been documented in a number of examples in
vitro, (Katayama et al., 2005; Faghihi et al., 2010; Morris et al.,
2008; Modarresi et al., 2012). In these cases, saRNAs might act by
preventing the repressive regulatory effects exerted by the AS
transcript on sense transcription (Fig. 1A). Consistently with this
inference, siRNA-mediated, Ago2-dependent knock-down of the
convergent p21 AS partner, Bx332409, was followed by the
detachment of the repressive epigenetic mark H3K27me3 from
the surroundings of the p21-TSS and by subsequent upregulation of
p21-mRNA (Morris et al., 2008). of nucleic acid-based therapy in the brain, Prog. Neurobiol. (2016),
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saRNAs may also act by helping to convey macromolecular
complexes catalyzing transcription to the gene of interest.
Interstingly, saRNA may directly interact with its target DNA
(Fig. 1B) (Hu et al., 2012) or via nascent ncRNA molecules, still
attached to chromosomal DNA (Fig. 1C) (Schwartz et al., 2008;
Matsui et al., 2013).
Among potential supporters of RNAa, Ago1 and Ago2 interact
with miRNAs and siRNA and are both detectable in the nucleus
(Huang et al., 2012). While the former has a scattered distribution
in the nucleoplasm, the latter is conﬁned to the peripheral region
adjacent the nuclear envelope (Huang et al., 2013). Ago1 binds
pervasively to chromatin, preferentially to TSS surroundings,
interacts with RNApolII and is involved in regulation of transcrip-
tion. As such, it was supposed to be speciﬁcally implicated in RNAa.
Unexpectedly, however, Ago1 is required for transcriptional gene
silencing (TGS) but not for RNAa (Chu et al., 2010; Li et al., 2006).
The same applies to its paralogs Ago3 and Ago4 (Chu et al., 2010).
Conversely, in a number of cases including those of p21 and E-
Cadherin (Li et al., 2006), PR (Chu et al., 2010), LDLR (Matsui et al.,
2010) and COX2 (Matsui et al., 2013), Ago2 resulted to be linked to
target gene chromatin (or ncRNAs stemming from it) in a saRNA-
dependent manner and required for RNAa activity. In the case of
COX2-RNAa, Ago2 and the saRNA were associated to GW182, which
was needed for RNAa as well (Matsui et al., 2013). The reason of
selective Ago2 requirement for RNAa remains obscure.
Beyond Ago2 and GW182, concomitantly with RNAa, other key
players are recruited to target gene chromatin or to RNAs
stemming from it. An enrichment of RNA polymerase II (RNApolII)Fig. 1. Putative mechanisms of saRNAs. (A) saRNAs may drive Ago2-dependent
degradation of nascent, noncoding RNAs, in charge of recruiting W and Z
polypeptidic trans-repressors to the gene of interest (goi). (B,C) Alternatively,
saRNAs may drive Ago2-dependent recruitment of X and Y polypeptidic
transactivators to the goi. The saRNA may directly interact with locally denatured
goi-DNA (B) or with a nascent ncRNA, stemming from goi chromatin (C).
Please cite this article in press as: S. Gustincich, et al., The Yin and Yang
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(Huang et al., 2012; Place et al., 2008; Matsui et al., 2010; Chu et al.,
2010; Yue et al., 2010; Majid et al., 2010). This suggests that saRNAs
often act by easing the recruitment of RNApolII to the target gene
promoter. Alternatively, miR-483 upregulated IGF2-mRNA, by
conveying the RNA helicase DHX9 to the CG-rich 50UTR of this
mRNA (Liu et al., 2013a). This suggests that saRNAs might also act
co-transcriptionally, possibly by destabilizing secondary struc-
tures peculiar to nascent pre-mRNAs and thus promoting their
elongation.
Remarkably, saRNAs delivery also leads to extensive and
complex changes of the covalent epigenetic proﬁle of chromatin.
Depending on the gene of interest, epigenetic changes triggered by
saRNAs included an increase of H3K4me2 and/or H3K4me3, H3ac
and H4ac, as well as a decrease of H3K9me2 and/or H3K9me3,
H3K27me3, H3K9ac and H3K14ac (Majid et al., 2010; Turunen
et al., 2009; Matsui et al., 2013; Huang et al., 2012; Janowski et al.,
2007; Modarresi et al., 2012; Li et al., 2006). Conversely, no change
in CpG methylation was reported at all.
In addition to covalent epigenetic changes, the functional link
between RNAa and chromosomal DNA looping is particularly
intriguing. As found by Chromosomal Conformation Capture (3C),
the 50 and the 30 ends of the PR gene physically interact in MCF7
cells. While not affecting the degree of this intragenic looping,
saRNAs captured ncRNAs stemming from the other end in RIP
assays when directed against the two different gene ends (Yue
et al., 2010). More remarkably, in A549 cells, targeting of the COX2
promoter by saRNA12 induced looping of the DNA interposed
between COX2 and Phospholipase A2 (PLA2G4A), whose protein
product is required for the synthesis of arachidonic acid, the COX2
substrate. With this mechanism, COX2 and PLA2G4A promoters,
which lie on the same chromosome almost 150 kb far from each
other in divergent orientation, got into close tridimensional
vicinity, leading to coordinated transactivation of both genes
(Matsui et al., 2013).
In conclusion, a wealth of information about “basic” molecular
events triggered by saRNAs is available nowadays. However, we do
not know the general causal order, if any, linking one another. In
particular, we presently ignore if the epigenetic events exempliﬁed
above are propedeutic to the transcription arousal occurring in
RNAa, or are a consequence of it. Further in depth studies will be
required to solve this issue.
6.5. RNA-programmable NMHV transcription factors
To expand the repertoire of molecular tools available for
therapeutic stimulation of gene transcription, one of our groups
recently developed a novel class of artiﬁcial transactivators,
termed NMHVs (an acronym standing for Nuclear localization
signal  MS2 coat protein RNA interacting domain  HA epitope 
(3x)VP16 transactivating domain) (Fig. 2) (Fimiani et al., 2015).
These are RNA-programmable enzymes like CRISPR-TFs, however
they differ from CRISPR-TFs in several aspects. First, they require
longer RNA baits for effective and speciﬁc target recognition (60
bases vs 20 bases). Moreover, compared to CRISPR, NMHVs (1) are
>7-folds smaller, (2) elicit a normalized transcriptional gain around
twofold, and (3) selectively stimulate transcription of active genes,
while not affecting silent ones. These traits are very different from
the corresponding features of more popular, RNA-programmable
CRISPR-TFs, which are very large, can switch on silent genes,
possibly because of their intrinsic helicase activity (Cheng et al.,
2013; Kearns et al., 2014), and easily achieve very high expression
gains, even >500-folds (Perez-Pinera et al., 2013). For these
reasons, CRISPR-transactivators would be hardly employable for
scalable and ﬁnely tuned correction of haploinsufﬁciencies.
Conversely, broad in vivo delivery of NMHV-TFs seem to be better of nucleic acid-based therapy in the brain, Prog. Neurobiol. (2016),
Fig. 3. Schematic representation of target mRNA and target-speciﬁc SINEUP. 50 to 30
orientation of sense mRNA and antisense SINEUP is indicated. Black arrows
represent transcription initiation and orientation. Structural elements of target
protein-coding mRNA (green): 50 untranslated region (50UTR), coding sequence
(CDS) and 30 untranslated region (30UTR). Initiating AUG is shown in red. Structural
elements of target-speciﬁc SINEUP (purple): Binding Domain (BD), SINEUP
sequence that overlaps, in antisense orientation, to the sense protein-coding
mRNA; Effector Domain (ED), inverted SINEB2 element (invB2) that confers
activation of protein synthesis. (For interpretation of the references to colour in this
ﬁgure legend, the reader is referred to the web version of this article.)
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insufﬁciencies. This prediction, as well as a more thorough
assessment of NMHV off-targeting effects, currently waits for
experimental validation.
6.6. SINEUPs
The use of long non-coding RNAs as biotechnology and
therapeutic tools is still at infancy. Some of us have recently
shown that AS Uchl1, a lncRNA antisense to the mouse ortologue of
the human Uchl1/Park5 gene, increases UchL1 protein synthesis at
post-transcriptional level (Carrieri et al., 2012). AS Uchl1 is a 50
head-to-head divergent antisense lncRNA, that partially overlaps
with Uchl1 mRNA covering initiating AUG. When overexpressed in
murine dopaminergic cell line, AS Uchl1 is able to increase UchL1
protein product without affecting its mRNA levels. Under
physiological conditions, AS Uchl1 is retained in the nucleus.
Upon rapamycin treatment, AS Uchl1 shuttles from the nucleus to
the cytoplasm with an unknown mechanism. Once in the
cytoplasm, AS Uchl1 induces Uchl1 mRNA association to heavy
polysomes, thus increasing its translation. We could demonstrate
that AS Uchl1 activity depends on the combination of two RNA
elements: at the 50 end, the overlapping region is indicated as the
Binding Domain (BD); while the 30 non-overlapping region
contains an embedded inverted SINEB2 element, which represents
the Effector Domain (ED) (Fig. 3). The ED is required for protein up-
regulation function of AS Uchl1 and the BD dictates its speciﬁcity
towards Uchl1 mRNA. By swapping BD sequences, a synthetic
lncRNA can be designed in which AS Uchl1 activity is re-directed to
target exogenous transcripts, as those encoding for Green
Fluorescent Protein (GFP) (Carrieri et al., 2012; Zucchelli et al.,
2015b). Therefore, AS Uchl1 can be considered the representative
member of a new functional class of AS lncRNAs that utilize
embedded inverted SINEB2 elements to increase translation of
partially overlapping protein-coding genes acting on their
endogenously expressed mRNAs (Carrieri et al., 2012; Zucchelli
et al., 2015b). These natural and synthetic molecules were named
SINEUPs since their function requires the activity of an embedded
inverted SINEB2 sequence to UP-regulate translation (Zucchelli
et al., 2015a, 2015b). SINEUPs are thus the ﬁrst example of gene-
speciﬁc inducers of protein synthesis. SINEUP modular structure
can be employed to artiﬁcially engineer their BD and design
synthetic SINEUPs to speciﬁcally enhance translation of virtually
any target gene of interest. Synthetic SINEUPs so far have been
proven effective with a number of targets, including GFP (Carrieri
et al., 2012), FLAG-tagged proteins (Zucchelli et al., 2015b),
secreted recombinant antibodies and cytokines (Patrucco et al.,
2015), thus showing SINEUP technology is scalable, once provided
the required target recognition with BDs. Most importantly,Fig. 2. Schematics of RNA-programmable NMHV transactivators. NMHV transacti-
vator harbors a polypeptidic NMHV apofactor and an RNA cofactor. The former
includes an NLS2 (nuclear localization signal, 2x), an MS2-like RNA binding domain
(RBD), an HA hemaggulitinin epitope and a VP163 TransActivating Domain (TAD).
The latter results from a multimerized MS2-interacting ﬁnger (MFn) and a 60–180
base long bait, for the recognition of transcription start site sequences.
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http://dx.doi.org/10.1016/j.pneurobio.2016.11.001synthetic SINEUPs can act on endogenous mRNAs in vitro and in
vivo, as demonstrated by speciﬁc SINEUPs designed to target genes
associated to neurodegeneration (PARK7/DJ-1 for PD) (Zucchelli
et al., 2015b) and brain developmental disorders (Indrieri et al.,
2016).
Over competing technologies aimed to increase quantities of a
protein of interest, SINEUPs present three major advantages: 1)
Induce a 2-to-5-fold up-regulation thus limiting side effects due to
exaggerated overexpression in gene therapy approach; 2) Act on
endogenous mRNAs in situ, restricting translation enhancement to
the time and space of endogenous gene expression, 3) Do not
trigger hereditable genome editing. Similarly to other nucleic acid-
based therapies for brain disorders, the ﬁnal outcome of SINEUPs-
based therapy will depend on reaching their target mRNAs in the
brain. The current renaissance in nucleic acid-based drugs will
provide the correct molecular tools for their delivery.
7. The Yang side of nucleic acid-based therapy: applications to
neurodegenerative diseases
7.1. Angelman syndrome
UBE3A is an imprinted gene encoding an E3 ubiquitin ligase.
Maternal deﬁciency of UBE3A is the primary cause of Angelman
syndrome, a disorder characterized by severe intellectual disability
and developmental delay, with behavioural deﬁcits and severe
speech impairment, associated to seizures and ataxia. Patients
with Angelman syndrome carry one intact copy of paternal UBE3A
gene, which is inactivated by an antisense nuclear-retained lncRNA
(UBE3A-AS). ASO treatment was developed to target UBE3A-AS (as
carried out in AntagoNAT-based therapy) to correct for silenced
UBE3A expression in Angelman Syndrom mouse model (Meng
et al., 2015). Intra-cerebroventricular injection of single-dose ASO
was well tolerated. After ASO treatment (4 weeks), UBE3A-AS
expression was reduced by 60–70% and ABE3A mRNA increased 2–
5 fold in brain and spinal cord. Correction of phenotypes was
evident but not complete.
7.2. Spinal muscular atrophy
Spinal muscular atrophy (SMA) is an autosomal recessive
disorder, caused by mutations in the SMN1 gene that result in a
deﬁciency of SMN protein that ultimately cause neuromuscular
defects. The severity of SMA is dictated in part by the copy number
of the related duplicated gene SMN2, which has a critical mutation
in the exonic splicing site of exon 7. Therapeutic strategies are
aimed at replacing insufﬁcient gene dosage by AAV delivery of
SMN1 cDNA. An alternative strategy is to use ASOs to re-direct
splicing of paralogue SMN2 RNA to boost expression of functional
SMN protein. Intra-cerebral ventricle injection into a mouse model
of severe SMA resulted in increased SMN protein levels, increased of nucleic acid-based therapy in the brain, Prog. Neurobiol. (2016),
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improvements in muscle physiology, motor function and survival
(Passini et al., 2011). In the same study, the SMN-speciﬁc ASO was
also injected intrathecally into non-human primates (cynomol-
gous monkeys) delivering therapeutic levels of the nucleotide drug
to all regions of the spinal cord.
Phase1/2 clinical trials have recently been completed to assess
safety, tolerability and the range of appropriate single intrathecal
dose of ASOs targeting SMN2 in patients with SMA (Chiriboga et al.,
2016; Hache et al., 2016). Phase 3 trials are currently ongoing for
infants. Additional trials were also initiated this year and are
currently enrolling a small subset of patients with infantile or
childhood-onset SMA (Faravelli et al., 2015) (and www.clinicaltrial.
gov, 2016).
7.3. Neurothrophic factor therapy
Neurotrophins, such as Brain-Derived Neurotrophic Factor
(BDNF), belong to a class of secreted neurotrophic factors that
are essentials for neuronal growth, differentiation and maintai-
nance. BDNF is also crucial for neuronal plasticity and has been
involved in learning and memory. Reduced levels of BDNF are
found in neurodegenerative diseases and are associated to
psychiatric and neurodevelopmental disorders. Therefore, upre-
gulation of BDNF is believed to have beneﬁcial effects on several
brain dysfunctions. Nucleic acid-based therapy has been employed
to increase BDNF quantities in the brain. Intranasal administration
of BDNF-encoding mRNA proved to be effective in repairing
olfactory epithelium architecture and rescuing olfaction defects in
a mouse model of olfactory dysfunction (Baba et al., 2015).
BDNF-AS is a negative regulator of BDNF levels, controlling
BDNF expression though recruitment of proteins belonging to
polycomb repressor complex. Inhibition of BDNF-AS using
antagoNATs increased BDNF mRNA and protein levels, ultimately
leading to neuronal outgrowth and differentiation in vitro and in
vivo (Modarresi et al., 2012).
Similarly, three distinct siRNAs, targeting convergent antisense
transcripts associated to Bdnf, elicited an early downregulation of
these transcripts, followed by a delayed and transient upregulation
of Bdnf-mRNA. Such Bdnf upregulation was not due to post-
transcriptional stabilization of the corresponding mRNA, but
reﬂects a speciﬁc reduction of the repressive epigenetic mark
H3K27me3 linked to the Bdnf-TSS. Consistently, two LNA-DNA
gapmers (aka antago-NATs, i.e. antagonists of natural antisense
transcripts), driving RNAse H-mediated degradation of Bdnf-AS,
fully recapitulated the effects of siRNA-like Bdnf activators
(Modarresi et al., 2012). Remarkably, by a similar approach, the
same authors also up-regulated Gdnf (Modarresi et al., 2012), a
neurotrophic factor regulating neurite branching and synaptic
plasticity (Airaksinen and Saarma, 2002), speciﬁcally down-
regulated in substantia nigra and putamen of PD patients
(Bäckman et al., 2006; Chauhan et al., 2001; Hunot et al., 1996),
as well as in cerebro-spinal ﬂuid and middle temporal gyrus of AD
patients (Airavaara et al., 2011; Straten et al., 2009).
Endogenous quantity of neurotrophic factors can be regulated
at the post-transcriptional level by networks of endogenous
miRNAs, whose expression is altered in brain of patients and in
animal models (Di Meco and Pratico, 2016; Zovoilis et al., 2011).
Therapeutic strategies aim at increasing neuroprotective factors by
inhibiting their physiological negative regulators. From miRNA
prediction programs, BDNF mRNA contains several hundreds of
miRNA target sites. Of these, a small number has been
experimentally validated and only miR-206 has been tested for
therapeutic intervention in vivo (Varendi et al., 2015). While
upregulated in AD brains, miR-206 has been shown to inhibit BDNF
by direct targeting its 30UTR, albeit contrasting results exists on thePlease cite this article in press as: S. Gustincich, et al., The Yin and Yang
http://dx.doi.org/10.1016/j.pneurobio.2016.11.001exact region of miRNA-mRNA interaction (Lee et al., 2012; Miura
et al., 2012; Tapocik et al., 2014). Viral-mediated overexpression of
miR-206 into the brain inhibited expression of BDNF in vivo in the
rat brain (Tapocik et al., 2014). Anti-miR-206 could restore levels of
BDNF, hippocampal synaptic density and neurogenesis while
improving memory in an AD mouse model (Lee et al., 2012).
7.4. Friedreich ataxia
Friedreich’s ataxia (FRDA) is a fatal untreatable neurodegener-
ative disease, mostly caused by the homozygous expansion of GAA
repeats, which leads to an insufﬁcient amount of frataxin protein.
Increasing quantities of frataxin protein in the brain and in the
heart is in principle curative. Delivery of corrected human frataxin
gene by adeno-associated viral vectors was sufﬁcient to reverse
cardiomyopathy (Perdomini et al., 2014) and improve symtoms
(Gerard et al., 2014) in mouse models of the disease. In addition to
these viral vector-mediated gene replacement strategies, recent
studies indicate the feasibility of mRNA-based and ASO-based
approaches for FRDA. Intratechal delivery of unmodiﬁed mRNA
encapsulated in lipid nanoparticles led to robust expression of
exogenous frataxin protein in the CNS and in dorsa root granglia, a
major site of pathology (Nabhan et al., 2016). Alternatively, the use
of single-stranded ASO targeting GAA repeat region rescued
frataxin protein levels in patient-derived ﬁbroblasts (Li et al.,
2016b).
Finally, in this respect, it may be of therapeutic interest that one
of our groups recently selected two artiﬁcial miRNAs targeting the
FXN promoter, eliciting a normalized FXN-mRNA gain up to 2.7 x in
immortalized lymphoblasts originating from homozygous FRDA
patients (Fimiani and Mallamaci, unpublished results). By this
gain, these cells expressed FXN-mRNA levels associated to healthy
heterozygous carriers (Pianese et al., 2004).
8. Conclusions
The recent years have been characterized by a new renaissance
in the ﬁeld of nucleic acid-based therapeutics and RNA therapeu-
tics in particular. Nowadays, it is possible to envision innovative
ways to treat neurodegenerative diseases. By exploiting nucleic
acid-based drugs we may hijack or interphere with regulatory
pathways modulating RNA and protein levels in time and space in
vivo. While inhibitory RNAs (Yin) are reaching clinical testing at an
unprecedented pace, recent advances in the ﬁeld of activatory
RNAs (Yang) are ready to pass the ﬁrst phase of discovery and
validation providing unprecedented tools in increasing therapeutic
protein levels in vivo. Whatever the RNA molecule to be delivered
(inhibitory siRNA or miRNA, activatory small or long non-coding
RNAs or sequence-corrected mRNAs) advances in the chemistry of
nucleic acids themselves or in their carrier nanoparticles will allow
a more efﬁcient and more precise targeting of brain tissues.
Similarly, the advent of new-generation adeno-viral vectors with
strongly selected brain tropism will eventually lead to new
efﬁcient strategies to solve one of the major issues for gene
therapy of neurodegenerative diseases.
The list of potential RNA-based intervention approaches to treat
neurodegenerative disorders cannot exclude guide RNA-assisted
CRISPR/Cas9 technology. Initially, CRISPR/Cas9 has been employed
to generate cellular and animal models of various diseases,
including those affecting the brain (Yang et al., 2016a). More
recently, RNA-guided endonuclease-based approaches have been
used for therapy. During this year, three groups have indepen-
dently reported that CRISPR/Cas9 could be used to remove the
affected allele in mouse dystrophin gene and revert disease
phenotype in mouse models of Duchenne Muscular Dystrophy
(Long et al., 2016; Nelson et al., 2016; Tabebordbar et al., 2016). of nucleic acid-based therapy in the brain, Prog. Neurobiol. (2016),
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mouse models of human hereditary liver diseases (Yang et al.,
2016b; Yin et al., 2016). For neurodegenerative disorders, provided
the appropriate delivery, CRISPR/Cas9 could represent a prowerful
tool to eliminate the expression of inherited autosomal dominant
mutated genes, as in Huntington’s disease or in some forms of
Parkinson’s disease. However, as for any genome-editing tool,
permament genome modiﬁcation represents a major drawback
with ethical concerns that will need to be speciﬁcally addressed in
the near future.
Finally, nucleic acid-based drugs, for their intrinsic scalability,
have the potentials to treat many neglected rare brain develop-
mental disorders that collectively affect an increasingly large
number of individuals.
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